Compare SAMG & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SAMG | CGTX |
|---|---|---|
| Founded | 2002 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 101.0M | 94.5M |
| IPO Year | 2012 | 2021 |
| Metric | SAMG | CGTX |
|---|---|---|
| Price | $13.30 | $0.96 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $3.33 |
| AVG Volume (30 Days) | 42.0K | ★ 1.5M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | ★ 6.43% | N/A |
| EPS Growth | N/A | ★ 62.79 |
| EPS | ★ 0.56 | N/A |
| Revenue | ★ $91,358,000.00 | N/A |
| Revenue This Year | $8.99 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $23.32 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.79 | $0.22 |
| 52 Week High | $16.97 | $3.83 |
| Indicator | SAMG | CGTX |
|---|---|---|
| Relative Strength Index (RSI) | 43.57 | 50.18 |
| Support Level | $13.27 | $0.55 |
| Resistance Level | $16.83 | $1.19 |
| Average True Range (ATR) | 0.57 | 0.13 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 31.06 | 63.89 |
Silvercrest Asset Management Group Inc is a wealth management firm focused on providing financial advisory and related family office services to ultra-high net-worth individuals and institutional investors. It advises clients on traditional investment strategies focused on equities, fixed income, and cash, as well as non-traditional investment strategies including hedge funds, private equity funds, real estate, and commodities. The firm offers a full suite of complementary and customized family office services for families seeking comprehensive oversight of their financial affairs. The company derives revenues from Managed accounts, Silvercrest funds, Tax and family office services, and Fund administration. The firm generates the majority of its revenue from Managed Accounts.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.